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Background: Autism spectrum disorders (ASD) and epilepsy frequently occur together. Prevalence rates are
variable, and have been attributed to age, gender, comorbidity, subtype of pervasive developmental disorder (PDD)
and risk factors. Recent studies have suggested disparate clinical and genetic settings depending on simplex or
multiplex autism. The aim of this study was to assess: 1) the prevalence of epilepsy in multiplex autism and its
association with genetic and non-genetic risk factors of major effect, intellectual disability and gender; and
2) whether autism and epilepsy cosegregate within multiplex autism families.
Methods: We extracted from the Autism Genetic Resource Exchange (AGRE) database (n = 3,818 children from
1,264 families) all families with relevant medical data (n = 664 children from 290 families). The sample included
478 children with ASD and 186 siblings without ASD. We analyzed the following variables: seizures, genetic and
non-genetic risk factors, gender, and cognitive functioning as assessed by Raven’s Colored Progressive Matrices
(RCPM) and Vineland Adaptive Behavior Scales (VABS).
Results: The prevalence of epilepsy was 12.8% in cases with ASD and 2.2% in siblings without ASD (P <10-5). With
each RCPM or VABS measure, the risk of epilepsy in multiplex autism was significantly associated with intellectual
disability, but not with gender. Identified risk factors (genetic or non-genetic) of autism tended to be significantly
associated with epilepsy (P = 0.052). When children with prematurity, pre- or perinatal insult, or cerebral palsy were
excluded, a genetic risk factor was reported for 6/59 (10.2%) of children with epilepsy and 12/395 (3.0%) of children
without epilepsy (P = 0.002). Finally, using a permutation test, there was significant evidence that the epilepsy
phenotype co-segregated within families (P <10-4).
Conclusions: Epilepsy in multiplex autism may define a different subgroup in terms of clinical characteristics
and genetic risk.
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Autism spectrum disorders (ASD) and epilepsy fre-
quently occur together. Approximately 5% to 40% of in-
dividuals with autism have epilepsy [1], whereas the
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reproduction in any medium, provided the or0.5% to 1%. Conversely, 5% to 30% of individuals with
epilepsy have ASD [2-5], whereas the prevalence of ASD
in the general population is about 1/150; although recent
studies reached even higher rates: 1/80 [6]. The variabi-
lity of prevalence rates have been attributed to the
heterogeneity of samples with respect to age, gender,
comorbidity, subtype of ASD, intellectual disability and
risk factors [7,8]. It may also result from the criteria used
to diagnose epilepsy. Finally, the genetic background of
autism may have a considerable impact on epilepsy rates
in autism.td. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Amiet et al. Molecular Autism 2013, 4:47 Page 2 of 16
http://www.molecularautism.com/content/4/1/47Recently, a meta-analysis of 24 reports on autism
and epilepsy confirmed intellectual disability and female
gender as major risk factors of epilepsy in autism [9]. The
pooled prevalence of epilepsy was 21.4% in individuals
with autism and intellectual disability versus 8% in indivi-
duals with autism without intellectual disability, and the
more severe the intellectual disability, the more prevalent
the epilepsy. With a male:female ratio of 2, the risk of
epilepsy was found significantly higher for females [9].
However, this might reflect the known circumstance that
females with autism tend to be more severely mentally
disabled [10].
Autism and epilepsy are both complex and heteroge-
neous disorders. Recent literature reviews underline the
important role of genetic factors in the etiology of ASD
[11-13]. Rare chromosomal abnormalities (for example
maternally inherited duplications of chromosome
15q11–q13) and single gene syndromes (for example
fragile X, tuberous sclerosis) are important risk factors
of ASD. More recently, individual genes of major effect
have been identified by resequencing or array-based
methods, but variants at these and other loci are present
in no more than 1% to 2% of children with ASD [14].
Some of these genes with major effects have been asso-
ciated with ASD, intellectual disability and/or seizures,
suggesting that the three disorders may share common
genetic risk factors (Table 1). Recent whole genome
DNA microarray studies have identified submicroscopic
duplications and deletions (copy number variations
(CNVs) located in many loci and mostly including
de novo events) in the same developmental disorders
(ASD, intellectual disability, epilepsy), and in schizophre-
nia as well [15-17] (Table 2).
However, all together, an identified genetic etiology is
estimated to account for 10% to 20% of ASD cases [15].
Therefore, in the majority of epilepsy cases, most autism
appears to be a multifactorial hereditary disorder,
depending on polygenic heredity and environmental
factors Environmental factors associated with autism are
mainly pre-, peri- and postnatal, such as in utero expo-
sure to teratogenic medications (for example thalidomide,
valproate) [121], prematurity, neonatal encephalopathy
and hyperbilirubinemia [122].
Most of the samples studied in autism are composed
of autistic individuals without information about
whether autism affects only one individual in the family
(simplex autism) or multiple siblings in the family
(multiplex autism). This is a major issue since higher
genetic risk may be hypothesized in multiplex autism.
Some recent studies have suggested disparate clinical
and genetic settings depending on simplex or multiplex
autism. More de novo rare mutations in genes of major
effect have been associated with simplex autism [108],
while an interactive effect of multiple commonsusceptibility alleles have long been hypothesized as risk
factors of familial autistic syndromes [123,124]. Whether
some clinical variables may help to delineate more
homogeneous subgroups in multiplex autism remains an
open question. Regarding epilepsy and ASD, only one
study specified that part of the sample included indivi-
duals with multiplex autism [125]. However, there was
no separate analysis of these two groups except to
observe that a similar incidence of electroencephalogram
(EEG) abnormalities was found. Banach et al. examined
gender differences and intellectual quotients (IQs), and
found no difference in non-verbal IQ between females
and males in multiplex families, while females had lower
non-verbal IQ scores than males in simplex families
[126]. However, the prevalence of major effect genetic risk
factors as a function of epilepsy, intellectual disability and
gender in multiplex families remains unknown.
The aims of the current study are: 1) to assess the
prevalence of seizures in multiplex autism and compare
it to the prevalence of siblings without ASD. Since
autism and epilepsy share common genetic risk factors,
we hypothesize a higher risk of epilepsy in individuals
with autism than siblings without ASD; 2) to compare
the prevalence of major effect genetic risk factors in
multiplex autism with and without epilepsy. We
hypothesize the group with epilepsy to have an increased
risk; 3) to assess whether autism and epilepsy co-segregate
within multiplex autism families; and 4) to assess whether
higher prevalence of epilepsy in multiplex autism is medi-
ated by intellectual disability and gender as it has been
shown in the literature [9].
Methods
Participants
Data were ascertained from all families participating in the
Autism Genetic Resource Exchange (AGRE) in September
2011. Families with two or more members diagnosed with
autism, pervasive developmental disorder-not otherwise
specified (PDD-NOS) or Asperger syndrome may enroll
in the AGRE program. Families register to the program
then AGRE recruitment staff follow-up with families
to confirm eligibility and complete the intake process.
Families were excluded from the AGRE program if they
had participated in another genetic study, a confirmed
neurogenetic disorder, a pre- or perinatal injury, prematurity
defined as delivery before 35 weeks of gestational age for
single births or before 33 weeks of gestational age for twin
births, a known chromosomal abnormality, or an abnormal
neurological examination.
The diagnosis of autism was made using the standard
Autism Diagnostic Interview-Revised (ADI-R) [127] with
three affected status categories based on ADI-R results:
autism, not quite autism (NQA) and broad spectrum. In
the current report, we fused the last two categories as
Table 1 Genes implicated in autism, epilepsy and/or intellectual disability
Gene Locus Mutation Transmission Phenotype Protein Reference(s)
SCN1A 2q24 Point mutation De novo ASD, E, ID Nav1.1 (Na
+ channel) [18-20]
Deletion Dominant inheritance
SCN2A 2q23–q24.3 Deletion De novo ASD, E, ID Nav1.2 (Na
+ channel) [20-22]
Point mutation Inherited
SCN3A 2q24 Deletion De novo E, ID Nav1.3 (Na
+ channel) [23,24]
SCN1B 19q13.1 Point mutation Dominant inheritance E β1 subunit (Na+ channel) [25]
KCNA1 12p13 Point mutation Dominant inheritance E, ID Kv1.1 (K
+ channel) [26,27]
KCNQ2 20q13.3 Point mutation Dominant inheritance E, ID KV7.2 (K
+ channel) [28,29]
Deletion De novo
KCNQ3 8q24 Point mutation Not known E KV7.3 (K
+ channel) [30]
KCNMA1 10q22 Point mutation Dominant inheritance ASD, E, ID KCa1.1 (K
+ channel) [31,32]
De novo
CACNA1A 19p13 Point mutation De novo E, ID CaV2.1 (Ca
2+ channel) [33]
Dominant inheritance
GABRA1 5q34–q35 Point mutation Dominant inheritance E Α1 subunit (GABAA receptor) [34]
GABRG2 5q34 Point mutation Dominant inheritance E, ID γ subunit (GABAA receptor) [35,36]
CHRNA2 8p21 Point mutation Dominant inheritance E α2 subunit (nACh receptor) [37]
CHRNA4 20q13.2–q13.3 Point mutation Dominant inheritance E, ID α4 subunit (nACh receptor) [38,39]
De novo
CHRNB2 1q21 Point mutation Dominant inheritance E β2 subunit (nACh receptor) [40]
De novo
NLGN3 Xq13.1 Point mutation Inherited ASD Inhibitory synapse formation [41]
NLGN4 Xp22.31 Point mutation Inherited ASD, ID Synapse formation [41,42]
Deletion
CDH8 16q21 Deletion Inherited ASD Synapse formation [43]
PCDH10 4q28.3 Deletion Inherited ASD Synapse formation [44]
PCDH19 Xq22 Deletion De novo E, ID Synapse formation [45]
Point mutation Inherited
NRXN1 2p16.3 Deletion Recessive inheritance ASD, E, ID, SCZ Synapse formation [46-48]
Point mutation De novo
CNTNAP2 7q35 Deletion Recessive inheritance ASD, E, ID, SCZ Synapse formation [49-51]
Point mutation De novo
SHANK2 11q13.4 Deletion De novo ASD, ID Synapse scaffolding [52]
Point mutation Inherited
SHANK3 22q13.3 Deletion De novo ASD, ID, SCZ Synapse scaffolding [53,54]
Point mutation Inherited
SYNGAP1 6p21.3 Point mutation De novo ASD, E, ID Synapse RasGAP [55,56]
Deletion Inherited, de novo
CDKL5 Xp22 Point mutation De novo E, ID Cyclin-dependent kinase-like 5 [57,58]
Deletion Inherited
ARX Xp22.13 Duplication Inherited ASD, E, ID Aristaless-related homeobox protein [59,60]
De novo
ATP1A2 1q21–23 Point mutation Dominant inheritance E, ID Sodium-potassium ATPase [61,62]
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Table 1 Genes implicated in autism, epilepsy and/or intellectual disability (Continued)
SLC2A1 1p35–p31.1 Deletion Dominant inheritance E, ID GLUT1 [63]
Point mutation De novo
Recessive inheritance
STXBP1 9q34.1 Point mutation Inherited E, ID Syntaxin-binding protein [64]
De novo
Adapted from Betancur [15] and Amiet [65]. ASD, autism spectrum disorders; E, epilepsy; GABA, γ-aminobutyric acid; GLUT1, glucose transporter type 1;
ID, intellectual disability; nACh, nicotinic acetylcholine; RasGAP, Ras GTPase activating protein; SCZ, schizophrenia.
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must exceed the ADI-R cutoff for autism in all domains.
Children meeting the following criteria were classified as
PDD-NOS: 1a) must meet cutoff scores for autism on the
three core domains (social, communication, behavior) but
not on the age of onset domain, or 1b) must be no more
than one point below the cutoff score on any of the three
core domains, while also meeting the cutoff for the age of
onset domain; and 2) must meet one or more of the
following: a) show a severe deficit in at least one domain, b)
show more moderate deficits in at least two domains,
and/or c) show only minimal deficits in all three domains.
The AGRE database consisted of 3,819 children from
1,264 families. We excluded the 3,150 children (1,837
children with autistic disorder, 226 children with PDD-
NOS and 1,087 children without autism) whose clinical
data gave no information about the presence or absence
of epileptic seizure. We excluded five more individuals
who were reported by their family with a diagnosis of
Asperger syndrome without any ADI-R available. We
included the 664 children from 290 families (417 children
with autistic disorder, 61 children with PDD-NOS and
186 children without autism) whose characteristics are
discussed below. We found no significant differences be-
tween excluded and included individuals for age at ADI-R
clinical assessment (mean (± SD)) (8.5 years (± 4.9) versus
8.1 years (± 4.7), respectively; P = 0.098), gender (68.1%Table 2 Copy number variations (CNVs) associated with autism
and schizophrenia
Cytoband Maximum coordinates Phenotype
1q21.1 144.9–146.2 ASD, E, ID, SCZ
3q29 197.1–198.9 ASD, E, ID, SCZ
7q11.23 71.9–74.2 ASD, E, ID, SCZ
15q11.2–13.1 21.1–26.2 ASD, E, ID, SCZ
15q13.3 28.2–30.7 ASD, E, ID, SCZ
16p11.2 29.4–30.1 ASD, E, ID, SCZ
16p11.2 29.4–30.1 ASD, E, ID
16p13.11 14.6–18.7 ASD, E, ID, SCZ
17q12 31.5–33.1 ASD, E, ID, SCZ
22q11.2 16.9–20.6 ASD, E, ID, SCZ
Adapted from Betancur [15], Johnson and Shorvon [17], and Levinson et al. [120]. A
ID, intellectual disability; SCZ, schizophrenia.versus 69.7% of boys, respectively; P = 0.43) and Raven’s
nonverbal IQ (100.2 (± 19.3) versus 99.8 (± 18), respect-
ively; P = 0.76). We found a significant difference in the
percentage of autistic disorder, PDD-NOS and unaffected
children (P = 0.002), but the difference accounted for a
higher percentage of unaffected children in the excluded
sample (34.6% versus 28.0%). In contrast with Raven’s non-
verbal IQ, we found a significant difference for Vineland
composite standard score (62.6 (± 21.6) versus 54.4
(± 20.4), respectively; P <10-10).
Measures
Data relevant to epilepsy
Most of the AGRE families had an extensive evaluation
by pediatricians, psychiatrists and/or neurodevelopmental
specialists in order to obtain medical and family history
information. Data relevant to epilepsy were extracted from
probands, and unaffected children’s medical history files
were provided by the AGRE database. These data were
collected through a standardized method by AGRE and
consist of the occurrence or not of afebrile seizures or
remote febrile seizures, the age of onset, and the number
of seizures and their type. After extraction from the AGRE
database, data were reviewed by a neurologist and three
groups were formed: epilepsy, remote febrile seizures
(meaning febrile seizures with an identified antecedent












SD, autism spectrum disorders; CNV, copy number variation; E, epilepsy;
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seizures.
Genetic and non-genetic risk factors of autism
For each of the 478 included individuals with ASD, we
determined whether there were known genetic and non-
genetic risk factors of autism. Despite the exclusionary
criteria described above, the database flags: 1) possible
syndromic autism based on clinical (significant dysmor-
phology, abnormal neurologic exams) and morphologic
criteria (abnormal imaging or medical tests); and 2)
pre- or perinatal injuries and prematurity (defined as
delivery before 35 weeks of gestational age for single
births and before 33 weeks of gestational age for twin
births). Also noted were: comorbid medical or psychiatric
disorders and genetic abnormalities identified by clinical
genetic investigation [128]. Most of the families of the
AGRE dataset were screened for fragile X syndrome using
PCR technique. About half of the AGRE families had been
karyotyped, and 228 (47.7%) were analyzed for small
nuclear ribonucleoprotein polypeptide N (SNRPN) dupli-
cation at 15q12 and 393 for telomere analyses for small-
scale deletions and duplications. A sample of 943 families
was genotyped using the HumanHap550 BeadChip
(Illumina, San Diego, CA, USA) [129] and a sample of 777
families was genotyped using the 5.0 Chip (Affymetrix,
Santa Clara, CA, USA) [130]. The details of these screenings
are available on the AGRE website (http://www.agre.org).
Of the 664 children included in this analysis, 35 (5.3%)
children from 33 families (31 children with autistic
disorder, two children with PDD-NOS and two children
without autism) were flagged as having strong risk
factors for both autism and seizures: pre- or perinatal
insult, prematurity before 35 weeks of gestational age
(19 children), chromosomal abnormality (eight children
with a known trisomy, translocation or inversion, and
one child with significant dysmorphology), or an abnormal
neurological or cerebral imaging examination (seven
children). We found no significant differences between
these children and their siblings and the children with no
flag for age on ADI-R clinical assessment (P = 024), gender
(P = 0.42), mean Raven’s non-verbal IQ (P = 0.17), mean
Vineland composite standard score (P = 0.80), or the
percentage of autistic disorder, PDD-NOS and unaffected
children (P = 0.17).
Raven’s Colored Progressive Matrices (RCPM)
Non-verbal intellectual capacity was measured by
Raven’s Colored Progressive Matrices (RCPM) [131].
The RCPM is a standardized test designed to measure
non-verbal intellectual capacity in children from the age
of 5 years. Scores on the RCPM correlate highly with
scores on tests of general intellectual capacity [132]. The
RCPM consist of 36 items, presented in three sets of 12,which become progressively more difficult. Each item
contains a pattern problem with one part removed and
six pictured potential inserts, one of which contains the
correct pattern. The number of correct answers is trans-
formed to a non-verbal IQ score based on age-dependent
normative data.
Vineland Adaptive Behavior Scales (VABS)
The adaptive functioning level was assessed by the Vineland
Adaptive Behaviors Scales (VABS). The VABS is a semi-
structured parental interview that evaluates adaptive
functioning in four domains: communication, daily living
skills, socialization and motor skills. Age equivalent scores
and standard scores are provided for each domain. Scores
across domains can be combined to create an overall adap-
tive behavior composite standard score. Depending on the
time of inclusion in AGRE, one of the two forms of the
VABS was used: the survey form [133] and the second
edition of the VABS (Vineland II) [134]. For the purposes
of the current study, the overall adaptive behavior
composite standard score was used.
Statistical analysis
R software, version 2.12.2, was used for the statistical
analysis. First, we compared affected individuals with
individuals without epilepsy. Fisher’s exact test was used
for analysis of the association between the qualitative vari-
ables. A Student’s t-test was used for the analysis of the
association between the quantitative variables and the
group variables. Second, we tested whether epilepsy co-
segregated within families. To do so, from the 290 families,
we first extracted the 179 families in which pairs of two
affected siblings had a complete dataset for epilepsy, since
permutation tests cannot be applied on missing data. Each
sib-pair was designated either concordant or discordant for
epilepsy status. In each of the 20,000 permutations, the
individuals with epilepsy were randomly assigned among
the 179 families, and the resulting number of concordant
sib-pairs was recorded. The P value is the fraction of per-
mutation in which the number of concordant sib-pairs
exceeded the number in the observed data. Third, admix-
ture analysis was used to determine the best-fit model for
the age at onset of seizure in ASD. Given the literature, we
hypothesized a model with two subgroups, including one
with seizure onset before the age of 5 years and another with
seizure onset close to adolescence. Finally, a multivariate
analysis (logistic regression) was performed to assess which
variables contribute to the risk of seizures.
To assess whether the inclusion of the 35 children
from 33 families who were flagged with strong risk factors
for autism and seizures biased our results, we performed
secondary analyses excluding all families with such
children. These analyses were performed on 586 children
from 257 families who had medical data about presence or
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disorder, 53 (9%) children with PDD-NOS and 171 (29.2%)
children without autism.
Results
Primary analyses were performed on 664 children from
290 families who had informative data about presence or
absence of epilepsy: 417 (62.8%) children with autistic
disorder, 61 (9.2%) children with PDD-NOS and 186
(28%) children without autism (Table 3). Secondary ana-
lyses were performed on 586 children from 257 families
after exclusion of children with strong risk factors for
autism and seizures.
Prevalence and type of epilepsy
The prevalence of epilepsy was 13.4% (56/417) among
cases with an autistic disorder, 8.2% (5/61) among cases
with PDD-NOS and 2.2% (4/186) among siblings without
autism (P <10-4). The risk of epilepsy was sevenfold higher
for children with ASD (autistic disorder or PDD-NOS)
when compared with their siblings without ASD (odds
ratio (OR) = 0.15; 95% confidence interval (CI): 0 to 0.4;
P <10-5). The prevalence of remote febrile seizures was
4.6% (22/478) in cases with an ASD and 2.7% (5/186) in
siblings without ASD (OR = 1.75; 95% CI: 0.63 to 5.99;
P = 0.38). The prevalence of one afebrile seizure was
14/478 (2.9%) in cases with an ASD and 0.5% (1/186) in
siblings without ASD (OR = 5.57; 95% CI: 0.84 to 237.1;
P = 0.08). Secondary analyses excluding children with
strong risk factors for autism and seizures yielded similar
results: the prevalence of epilepsy was 12.2% (44/362) in
cases with an autistic disorder, 5.7% (3/53) in cases with
PDD-NOS and 2.3% (4/171) in siblings without autism
(P = 0.0002).
The mean age of children with ASD was 9.2 years
(± 5.0) at the time of their clinical assessment. Children
with ASD and epilepsy were significantly older (mean
age: 12.8 years ± 8.6) than children with ASD without
epilepsy (mean age: 8.7 years ± 4.0) (P <10-8). Mean age
of the first seizure was 4.7 years (± 3.8). Figure 1 sum-




Mean age (years) 9.33 (± 5.02)
Epilepsy 56 (13.4%)
Remote febrile seizures 16 (3.8%)
One afebrile seizure 14 (3.4%)
Risk factors for ASD 39 (9.6%)
Risk factors for ASD and comorbid seizures 10 (2.5%)
Performed on 664 children and 290 families. ASD, autism spectrum disorders; PDD-age. Given the 4-year older age of children with epilepsy,
the distribution of age of individuals with ASD without
epilepsy, and of individuals with ASD and epilepsy, is
also given. As several reports showed that there may be
distinct ages at onset of subgroups among individuals
with epilepsy, we conducted an admixture analysis to
test whether the observed distribution for age at onset in
individuals with ASD and seizure (n = 55) was a mixture
of Gaussian distributions. A parametric bootstrap with
B = 500 replications of the likelihood ratio statistic was
performed for testing the null hypothesis of a one-
component fit versus the alternative hypothesis of a two-
component fit. The result was significant (P <0.001) and
therefore the model with two components was adequate.
The mean ages estimated in this model were 2.3 years
(± 1.3) and 8.3 years (± 3.5) (Figure 2). All types of
seizures were reported in children with autism and
epilepsy (n = 61): 12 (19.7%) children had generalized
seizures, 17 (27.9%) children had absences, 14 (23.0%)
children had complex partial seizures, 11 (18.0%)
children had multiple seizure types, and the type of seizure
was unknown for seven (11.5%) children.
Secondary analyses excluding children with strong risk
factors for autism and seizures yielded similar results:
mean age of ASD children = 9.1 years (± 4.7); mean age of
ASD and epilepsy children = 12.4 years (± 7.0) versus
mean age of ASD children without epilepsy = 8.7 years
(± 4.1) (P <10-6); mean age at the first seizures = 5.2 years
(± 4.1); similar proportions of generalized seizures (21.3%),
absences (27.7%), complex partial seizures (23.4%), mul-
tiple seizures types (19.1%), and unknown (8.5%).
Co-segregation analyses and prevalence of genetic
and non-genetic risk factors as a function of epilepsy
Of the 478 children with ASD, 464 (97.1%) children
underwent genetic testing (karyotyping and/or array com-
parative genomic hybridization (aCGH), and/or genome-
wide association (GWA)). A total of 42 (8.8%) children
had a known possible genetic or non-genetic risk factor
for autism (39 children with autistic disorder, three chil-
dren with PDD-NOS; Table 4). In decreasing frequency,ording to clinical status
PDD-NOS Total (ASD) Siblings without autism
61 478 186
48/13 382/96 81/105
8.67 (± 5.01) 9.24 (± 5.02) 10.56 (± 6.59)
5 (8.2%) 61 (12.8%) 4 (2.2%)
6 (9.8%) 22 (4.6%) 5 (2.7%)
0 (0%) 14 (2.9%) 1 (0.5%)
3 (5.4%) 42 (8.8%) 0
0 10 (2.2%) 0



















age of first seizures age of individuals with ASD and epilepsy
age of individuals with ASD without epilepsy 
Figure 1 Distribution of age of first seizure, age of individuals with ASD and epilepsy, and age of individuals with ASD without
epilepsy. Age of first seizure (n = 55, black), age of individuals with ASD and epilepsy (n = 61, green or grey), and age of individuals with ASD
without epilepsy (n = 417, white and blue). ASD, autism spectrum disorders.
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(n = 19), chromosomal abnormality (n = 14), abnormal
cerebral imaging or significant developmental abnormality
(n = 3), comorbid medical disease associated with ASD
(n = 4), and cerebral palsy (n = 2). An epilepsy was reported
for ten children (all had autistic disorder). Genetic or non-
genetic risk factors of autism tended to be signifi-
cantly associated with epilepsy (OR = 2.25; 95% CI: 0.93 to
5.04; P = 0.052). When children with prematurity, pre- orFigure 2 Theoretical distribution of ages of onset of seizures
for 55 individuals with comorbid multiplex autism with
epilepsy. Distribution shows two subgroups with early onset of seizures
(mean = 2.3 years (± 1.3)) and late onset of seizures (mean = 8.3 years
(± 3.5)). A parametric bootstrap with B = 500 replications of the likelihood
ratio statistic was performed for testing the null hypothesis of a one-
component fit versus the alternative hypothesis of a two-component fit.
The result was significant (P= 0) and therefore the model with two
components was adequate.perinatal insult, or cerebral palsy were excluded, a known
or possible genetic risk factor was reported for 10.2% (6/59)
of children with epilepsy and 3.0% (12/395) of children
without epilepsy (OR = 3.6; 95% CI: 1.06 to 10.9; P = 0.02).
Finally, there was significant evidence that epilepsy co-
segregated within autism sib-pairs. Indeed, among the
179 families with sib-pairs affected by ASD, we found
154 sib-pairs concordant (meaning both siblings with
ASD had epilepsy or did not have epilepsy) for asso-
ciated epilepsy, while 25 sib-pairs were discordant (permu-
tation: P <10-4). Secondary analyses excluding children
with strong risk factors for autism and seizures yielded
similar results: among the 155 families with sib-pairs
affected by ASD, we found 132 sib-pairs concordant for
associated epilepsy, while 23 sib-pairs were discordant
(permutation test: P = 0.0049). Table 5 details the 11
AGRE families with two children with ASD and comorbid
epilepsy, showing clinical status, type of seizure and
known risk factors in all siblings.
Epilepsy and non-verbal IQ/adaptive level
Given the heterogeneity of general cognitive function in
ASD, we used two measures to assess whether epilepsy
was associated with intellectual disability in multiplex
autism. An assessment with the RCPM was applied to
438 children with ASD (381 children with an autistic
disorder and 57 children with PDD-NOS). One hundred
forty-three children were not testable and ten children
scored above the highest possible age-specific non-
verbal IQ, without numeric scores available. The mean
non-verbal IQ of children with ASD (n = 285) was 99.6
(± 18.0). Stratification of cases into two categories:
IQ <70 (n = 17) and IQ ≥70 (n = 278) showed a fivefold
increased risk of epilepsy for children with an IQ <70
(7/17; 41.2%) comparing children with an IQ ≥70
(31/278; 11.2%) (OR = 5.5; 95% CI: 1.7 to 17.5; P = 0.005).
Table 4 Risk factors of autism in the AGRE sample according to epilepsy
Risk factors Total (n) Epilepsy (n) No epilepsy (n)
Total of individuals 478 63 415
Chromosomal abnormality or genetic condition 14 (2.92%) 4 (6.35%) 10 (2.4%)
16p11.2 deletion/duplication 4 2 2
15q11–13 duplication 3 1 2
22q11.21 duplication 1 0 1
22q13.33 duplication 1 0 1
t(2;9)(p13;q34.3) 1 1 0
Mosaic t(3;16) 1 0 1
Mosaic t(3;14) 1 0 1
Trisomy 21 1 0 1
Mosaic trisomy 12 1 0 1
Prematuritya/pre- or perinatal insult 19 (3.98%) 3 (4.76%) 16 (3.9%)
Cerebral palsy 2 (0.42%) 0 2 (0.48%)
Abnormal cerebral imaging 3 (0.63%) 2 (3.17%) 1 (0.24%)
Agenesis of corpus callosum 1 1 0
Left frontal damage 1 1 0
Not given 1 0 1
Other significant abnormality 4 (0.84%) 1 (1.59%) 3 (0.72%)
Significant dysmorphology 2 0 2
Mitochondrial disorder, mild tonsillectomy (premature puberty) 1 1 0
Cranial nerve paralysis (congenital versus traumatic) 1 0 1
Total of individuals with abnormalitiesb 42 (8.8%) 10 (15.9%) 32 (7.71%)
aDefined as delivery before 35 weeks of gestational age for single births or before 33 weeks of gestational age for twin births; bP = 0.052. AGRE, Autism Genetic
Resource Exchange.
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children with ASD (336 children with an autistic dis-
order and 50 children with PDD-NOS). The mean over-
all adaptive behavior composite standard score of
children with ASD was 54.0 (± 20.2). Stratification of
cases into two categories: composite standard score <70
(n = 294) and composite standard score ≥70 (n = 92)
showed a threefold increased risk of epilepsy for children
with a composite standard score <70 (45/294 (15.3%))
comparing children with a composite standard score
≥70 (5/92 (5.4%) (OR = 3.1; 95% CI: 1.2 to 10.5;
P = 0.015). Figure 1 depicts the frequency of comorbid
epilepsy in individuals with ASD as a function of compos-
ite standard score. The more severe the impairment of
adaptive level, the more prevalent the epilepsy (P = 0.002).
Epilepsy and gender
Among the 96 females with a diagnosis of ASD (autistic
disorder or PDD-NOS), 16.7% (n = 16/96) had epilepsy.
For the 382 males with ASD, 11.8% (45/382) had epi-
lepsy. The male:female ratio was 4.2 for the children
with ASD without epilepsy, and 2.9 for the children withASD and with epilepsy. However, the difference was not
statistically significant (OR = 0.7; 95% CI: 0.3 to 1.3;
P = 0.268). Considering all the children with ASD
regardless of their epileptic status, the male:female ratio
was not significantly different when the sample was
stratified into two groups (normal intelligence versus
intellectual disability) based on the non-verbal IQ (RCPM:
≥70, n = 278; <70, n = 17) (male:female ratio = 3.3 versus
4.5, respectively) (OR = 0.7; 95% CI: 0.2 to 3.2; P = 0.788)
or the adaptive level (VABS: ≥70, n = 92; <70, n = 294)
(male:female ratio = 3.4 versus 3.9, respectively) (OR = 1.2;
95% CI: 0.6 to 2.1; P = 0.664). Furthermore, there was no
difference when the sample was stratified into four groups
based on the adaptive level (<40, 40 to 54, 55 to 69, ≥70;
P = 0.591).
Multivariate analysis
To confirm univariate variables associated with the risk of
seizures, we used a logistic regression. ASD (estimate =
2.49, P = 1.1 10-5; OR = 12; 95% CI: 4.46 to 43.1), age
(estimate = 0.11, P = 1.1 10-6; OR = 1.15; 95% CI: 1.07
to 1.17) and gender (male: estimate = −0.61, P = 0.049;
Table 5 AGRE families with two children with ASD and comorbid epilepsy (n = 11): clinical status, type of seizures and
risk factors in all siblingsa
Family Gender Autism diagnosis Type of seizureb Risk factor of ASD and/or epilepsy
AU0025 M Autism Partial Mitochondrial disorder, mild tonsillectomy (premature puberty)
M Autism Multiple No risk reported
F Unaffected No seizure Unknown
AU0051 M Autism Absence No risk reported
M Autism Absence Agenesis of corpus callosum
AU0123 F Autism Partial Prematurityc/pre- or perinatal insult
M Autism Multiple Unknown
F Unaffected No seizure Unknown
AU0176 F Autism Partial No risk reported
M Autism Partial No risk reported
M Unaffected No seizure Unknown
F Unaffected No seizure Unknown
AU0275 M Autism Multiple No risk reported
M Autism Not indicated Unknown
F Unaffected No seizure Unknown
F Unaffected No seizure Unknown
AU0461 M Autism Generalized No risk reported
M Autism Generalized Unknown
AU0548 F Autism Absence No risk reported
M Autism Not indicated No risk reported
F Unaffected No seizure Unknown
AU0731 M Autism Generalized Prematurityc/pre- or perinatal insult
M PDD-NOS Not indicated Unknown
AU0765 M Autism Absence Unknown
F PDD-NOS Not indicated t(2;9)(p13;q34.3)
M Unaffected No seizure Unknown
AU0922 M Autism Partial No risk reported
F Autism Partial Unknown
AU1208 M Autism Multiple 15q11–13 duplication
M Autism Absence Unknown
aFrom the 154 families included in the co-segregation analysis, the families with ASD children and without epilepsy are not detailed in this table; bnot indicated
means that the type of seizures was not given in the AGRE database, although the patient exhibits epilepsy; cdefined as delivery before 35 weeks of gestational
age for single births or before 33 weeks of gestational age for twin births. AGRE, Autism Genetic Resource Exchange; ASD, autism spectrum disorders; PDD-NOS,
pervasive developmental disorder-not otherwise specified.
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risk of seizure. In ASD individuals only, gender was not
significantly associated, whereas age and intellectual dis-
ability were significantly associated, whether intellectual
disability was measured with VABS (estimate = 1.15,
P = 0.02; OR = 3.2; 95% CI: 1.3 to 9.6) or with RCPM
(estimate = 1.57, P= 0.005; OR= 4.85; 95% CI: 1.53 to 14.56).
Discussion
Epilepsy in autism has been a subject of increasing interest,
and reported prevalence rates of seizures in this conditionvary from 5% to 40% [1]. The variability of rates have been
attributed to the heterogeneity of samples with respect to
age, gender, comorbidity, subtype of pervasive developmen-
tal disorder (PDD), intellectual disability and risk factors
[9]. But most of the studies have been conducted in
samples with simplex autism; for example the prevalence
found in the Simons Simplex Collection (a large multisite
phenotypic and DNA collection that includes families
(n = 2,644) in which there is only one child (aged 4 to
17 years) with ASD) is 2.4% [135]. In multiplex families, we
found that 13.4% of children with autism and 8.2% of
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the range of prevalence rates described in the literature. In
these multiplex families, we found that 2.2% of the siblings
without autism had epilepsy. This prevalence rate is high
compared to the general population where 0.7% to 0.8% of
children up to the age of 15 years have repeated seizures
[136]. Moreover, the permutation tests performed in this
study show significant evidence that epilepsy phenotypes
co-segregated within families.
Studies suggest that there are two peaks of onset of sei-
zures in autism, one in early childhood (before the age of
5 years old), and one near adolescence [137]. In the sample
studied here, the admixture analysis confirms this two-peak
model: 62% of the children had their first seizures before the
age of 5 years. Mean age of onset for the second peak is in
pre/early adolescence as only 9% of the children had their
first seizure after the age of 12 years. However, with a mean
age of 9.2 years, the children studied are relatively young and
many of them had not yet reached adolescence. Therefore,
it is likely that our estimate of the age of onset for the later
peak may be spuriously low as we cannot rule out that
epilepsy could begin later for some individuals. Unfortu-
nately, conducting a subanalysis with individuals aged
16 years and older was not possible given the sample size.
The risk of epilepsy in individuals with simplex autism
was significantly associated with intellectual disability
and gender. In a meta-analysis of 17 studies, the pooled
prevalence of epilepsy was 21.5% in individuals with
autism and intellectual disability, against 8% in individuals
with autism and normal intelligence [9]. Of note, the
increased risk with gender in simplex autism may reflect
the known circumstance that females with autism tend
to have more severe intellectual disability: the more severe
the intellectual disability, the lower the male:female ratio
[10]. In the present study, the respective prevalence rates of
epilepsy was 41.2% in individuals with autism and intellectual
disability, against 11.1% in individuals with autism and nor-
mal intelligence (P= 0.005), and the more the adaptive be-
havior level was impaired, the higher the prevalence of
epilepsy (Figure 3). However, there was no increase of epi-
lepsy linked to gender in individuals with ASD. Furthermore,
no significant difference in IQ among males and females was
found in the AGRE sample. A similar result was suggested in
previous reports of multiplex families [126,138].
Identification or strong suspicion of a risk factor for
autism (genetic or not) tended to increase the prevalence
of epilepsy. The non-genetic risk factors identified were
mainly perinatal fetal distress, the implication of which
for autism, epilepsy and intellectual disability is well
known. The prevalence of epilepsy remained significantly
higher even when only identified or suspected genetic risk
factors were considered. Genetic risk factors may be more
often implicated when autism and epilepsy are associated
[139]. This is also the case in multiplex families.Interpretation of the informative families presented in
Table 5 requires consideration of the AGRE database
limitations, which include: excluding individuals with
major perinatal risk factors or with known genetic
abnormalities (for example fragile X syndrome) (but
some siblings with such risk factors may have been
included); and in many individuals, data are unknown or
missing (for example not all individuals underwent CNV
search; see Methods). Also, large family histories including
epilepsy and ASD statuses of all members were not
available. Careful scrutiny of Table 5 shows that several
combinations of risk can lead to a multiplex pedigree: 1)
the existence of a common risk factor for epilepsy and
autism leading to the suggestion of screening for known
genetic risk factors of epilepsy in AGRE families AU25,
AU51, AU176, AU275, AU461, AU548 and AU922; and 2)
the co-occurrence of two different risk factors (genetic
and non-genetic ones) leading to a false ‘multiplex
pedigree’, such as in families AU731, AU123, AU765 and
AU1208; and 3) combinations of major and minor risk
factors as it cannot be excluded that a) in some families
interpretation of genotype/phenotype relationship may be
particularly complex (for example AU25, AU51) and b)
the same ASD genetic risk factor may be responsible for
increased risk of prematurity (for example AU731).
In terms of pathophysiological mechanisms, several
hypotheses have been proposed to explain the comorbidity
between autism and epilepsy: 1) accidental co-occurrence
given the high frequency of both conditions; 2) altered
internal organization of minicolumns in the cortex of
autistic individuals may be associated with a defect in
inhibitory local circuit projection, and the defect in
γ-aminobutyric acid (GABA)ergic fibers may correlate
with the increased prevalence of seizures in autism
[140,141]; 3) common genetic or neurodevelopmental risk
factors; and 4) epilepsy by itself may induce the develop-
ment of autistic symptoms [142]. Indeed, early-life seizures
may affect synaptic plasticity through alteration of neuro-
transmitter receptor systems and molecules essential for
intrinsic neuronal function, and changes that may contri-
bute to an enhanced risk of autism [143,144]. Supporting
this hypothesis, infantile spasms and/or early-onset
seizures have been significantly associated with autism
[145-147]. In the present study, few children had seizures
in their first year of life (11/63, 17%) and none had infantile
spasms. Thus, this mechanism may not account for much
of the high prevalence found. As stated previously, in indi-
viduals with autism from multiplex families, common
pathophysiological mechanisms appear to be more preva-
lent and may be genetic. If both autism and epilepsy can be
considered as disorders of synaptic plasticity [143,144],
autism and epilepsy may be the consequences of the same
pathophysiological mechanisms, resulting in abnormal plas-
ticity of genetic origin. Numerous genetic conditions that
Figure 3 Frequencies of comorbid epilepsy in children (n = 386) with autism from multiplex families as function of the Vineland
Adaptive Behavior Scales (VABS) composite standard score.
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are caused by mutations in genes implicated in synaptic de-
velopment, functioning and/or plasticity, such as Angelman
syndrome [148], fragile X syndrome [149], Rett syndrome
[150] and tuberous sclerosis [120,151]. Furthermore, mis-
sense and nonsense mutations of several genes involved in
neurodevelopment have been identified in individuals with
epilepsy, autism or both (Table 1). Most of those genes are
involved in cerebral development pathways and function-
ing: synaptic formation (NLGN4, NRXN1, CDH8, PCDH19,
SHANK3), ionic channel subunits (SCN1A, SCN2A,
SCN1B, KCNMA1, KCNQ2, CACNA1A) and neurotrans-
mitter receptors (GABRG2, CHRNA4). Similarly, CNVs
such as 1q21.1, 3q29, 7q11.23, 15q11–13, 15q13.3, 16p11.2,
16p13.11, 17q12 and 22q11.2 have been implicated in dif-
ferent developmental disorders, such as ASD, intellectual
disability and epilepsy [15,17,152], as well as schizophrenia
[16,152,153] (Table 2). Autism, epilepsy and intellectual dis-
ability may share alteration of common pathways involved
in neurodevelopmental maturation and neural functioning.
We propose that these genes need to be more systematic-
ally investigated as major and minor risk factors.
Although the current study was conducted in the largest
available sample of multiplex families, limitations should
be listed. First, we cannot exclude biases in recruitment
due to exclusion criteria as evidenced by the very low rate of
infantile spasm in the sample. Furthermore, of the 664 chil-
dren included in this analysis, 35 children (31 children with
autistic disorder, two children with PDD-NOS and two chil-
dren without autism) had strong risk factors for autism and
seizures, such as pre- or perinatal insult/prematurity before
35 weeks (n = 19), chromosomal abnormality (n = 8), or
abnormal neurological or brain imaging examination (n = 7).
However, when analyses were performed excluding these
children and their siblings, the results remained unchanged
(see also Additional file 1). Second, individuals’ ages were
significantly different in children with autism with epilepsy,and children with autism without epilepsy, and the small
number of adolescents may have reduced the prevalence of
late onset seizures. Third, given the heterogeneity of intellec-
tual functioning in autism and the heterogeneity of intellec-
tual disability measures, we used two standardized tools for
the cognitive and adaptive assessment: RCPM and VABS.
Assessing a broad sample of 38 autistic children, Dawson
et al. found scores on the RCPM to be, on average, 30 per-
centile points higher than their scores on the Wechsler scale
of intelligence [154]. The VABS assess the adaptive function-
ing with a parent interview. Strong positive relationships
have been found between Vineland composite and Vineland
subscales (communication, socialization, daily living skills)
and IQ, particularly when considering low functioning indi-
viduals [155]. Therefore, the two scales can be considered as
complementary for the cognitive assessment of children
with autism. The fact that we found similar results in the
AGRE sample strengthens this view. Fourth, we cannot
exclude that the absence of association with gender was
related to our final sample size and a lack of statistical
power. To assess this issue, we decided to perform a meta-
analysis in a larger sample including other studies reporting
IQ in multiplex pedigrees [126,138]. The standardized mean
difference between mean non-verbal IQ in males versus
females from multiplex pedigrees was 0.01 (95% CI: –0.17;
0.19), meaning that there is no difference between mean
non-verbal IQ according to gender (Additional file 2: Figure
S1). The meta-analysis confirmed our results.
Conclusion
We conclude that epilepsy in multiplex autism may define
a different subgroup in terms of clinical characteristics
and genetic risk: association with intellectual disability, no
association with gender and possible common risk factors.
Future studies should be encouraged to increase
knowledge of common genetic risk factors between ASD
and epilepsy.
Amiet et al. Molecular Autism 2013, 4:47 Page 12 of 16
http://www.molecularautism.com/content/4/1/47Additional files
Additional file 1: Secondary analyses.
Additional file 2: Figure S1. Standardized mean difference between
mean non-verbal IQ in males versus females from multiplex pedigrees:
a meta-analysis of three multiplex autism pedigrees (n = 719).
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